topotecan has been researched along with mitoxantrone in 68 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (8.82) | 18.2507 |
| 2000's | 41 (60.29) | 29.6817 |
| 2010's | 21 (30.88) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Imai, Y; Sugimoto, Y; Tsukahara, S; Tsuruo, T; Ueda, K | 1 |
| Allen, JD; Buitelaar, M; Schinkel, AH; Van Dort, SC; van Tellingen, O | 1 |
| Gibbons, S; Kaatz, GW; Zloh, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Friedrich, TD; Guzzo, PR; Jason Herr, R; Nacro, K; Peace, D; Zha, CC | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Ghosh, I; Manoharlal, R; Prakash, O; Prasad, R; Puri, N; Sharma, M | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cowan, KH; Horton, JK; Schneider, E; Yang, CJ | 1 |
| Ganapathi, R; Grabowski, D | 1 |
| Tannock, IF; Vukovic, V | 1 |
| Allen, JD; Brinkhuis, RF; Schinkel, AH; Wijnholds, J | 1 |
| de Jong, LA; Floot, BG; Maliepaard, M; Pluim, D; Ruevekamp-Helmers, MC; Schellens, JH; van Gastelen, MA; van Waardenburg, RC | 1 |
| Bates, SE; Brangi, M; Ciotti, M; Fojo, T; Kohlhagen, G; Litman, T; Nishiyama, K; Pommier, Y; Robey, R; Takimoto, C | 1 |
| Allen, JD; Dalton, WS; de Jong, MC; Maliepaard, M; Pijnenborg, AC; Ross, DD; Scheffer, GL; Schellens, JH; Scheper, RJ; Schroeijers, AB; van der Kolk, DM; van der Valk, P; van Gastelen, MA | 1 |
| Beijnen, JH; Brinkhuis, RF; Jonker, JW; Maliepaard, M; Schellens, JH; Schinkel, AH; Smit, JW | 1 |
| Beijnen, JH; Jonker, JW; Maliepaard, M; Scheffer, GL; Schellens, JH; Scheper, RJ; Schinkel, AH; Smit, JW | 1 |
| Kancherla, R; Nair, JS; Seiter, K; Traganos, F; Tse-Dinh, YC | 1 |
| Beggiolin, G; Carenini, N; Carminati, P; De Cesare, M; De Isabella, P; Palumbo, M; Perego, P; Pezzoni, G; Pisano, C; Pratesi, G; Scheffer, GL; Tartaglia, L; Zunino, F | 1 |
| Bates, SE; Dean, M; Honjo, Y; Hrycyna, CA; Litman, T; Medina-Pérez, WY; Robey, RW; van de Laar, A; Yan, QW | 1 |
| Battmer, K; Dammann, E; Eder, M; Ganser, A; Hambach, L; Heil, G; Hertenstein, B; Stucki, A | 1 |
| Imai, Y; Ishikawa, E; Sugimoto, Y; Tsukahara, S; Tsuruo, T | 1 |
| Chen, S; Gomez, SP; Mainwaring, MG; McCarley, D | 1 |
| Duan, Z; Kronish, KM; Lamendola, DE; Penson, RT; Seiden, MV | 1 |
| Braylan, R; Chen, SF; Fieniewicz, KJ; Gomez, SP; Kahn, S; Leather, H; Lynch, J; Mainwaring, MG; May, WS; Moreb, J; Reddy, V; Rimsza, LM; Rowe, TC; Weeks, FW; Wingard, JR | 1 |
| Abbott, BL; Andreeff, M; Barnes, Y; Colapietro, AM; Marini, F; Sorrentino, BP | 1 |
| Allen, JD; Koomen, GJ; Lakhai, JM; Reid, G; Schellens, JH; Schinkel, AH; van der Valk, M; van Loevezijn, A; van Tellingen, O | 1 |
| Imai, Y; Ishikawa, E; Kage, K; Miki, Y; Nakane, M; Sugimoto, Y; Tsukahara, S; Tsuruo, T | 1 |
| Fedier, A; Fink, D; Haller, U; Lenherr, L; Schwarz, VA; Steiner, RA | 1 |
| Huang, F; Lu, HZ; Wu, DL | 1 |
| Doi, S; Kamihira, S; Kawabata, S; Kitazaki, T; Kohno, S; Nakamura, Y; Nakatomi, K; Oka, M; Shiozawa, K; Soda, H; Sugahara, K; Tsurutani, J; Yamada, Y | 1 |
| Doi, S; Ikegami, Y; Kitazaki, T; Kohno, S; Mizuta, Y; Murase, K; Nakamura, Y; Nakatomi, K; Oka, M; Ross, DD; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M | 1 |
| Darzynkiewicz, Z; Holden, E; Huang, X; Luther, E; Okafuji, M; Traganos, F | 1 |
| Bolaños-Meade, J; Gojo, I; Guo, C; Karp, JE | 1 |
| Beck, WT; Ee, PL; He, X; Ross, DD | 1 |
| Doi, S; Ikegami, Y; Itoh, A; Kitazaki, T; Kohno, S; Nakamura, Y; Nakatomi, K; Oka, M; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M | 1 |
| Coburn, RA; Morris, ME; Wang, Q; Yang, X; Zhou, XF | 1 |
| Dai, W; Darzynkiewicz, Z; Halicka, HD; Huang, X; Kurose, A; Tanaka, T; Traganos, F | 1 |
| Dai, Y; Gupta, A; Hebert, MF; Mao, Q; Ross, DD; Thummel, KE; Unadkat, JD; Vethanayagam, RR | 1 |
| Dai, W; Darzynkiewicz, Z; Huang, X; Kurose, A; Tanaka, T; Traganos, F | 1 |
| Banerji, S; Los, M | 1 |
| Beijnen, JH; Borst, P; Breedveld, P; Cipriani, G; Dahlhaus, F; de Wolf, CJ; Jansen, G; Kuil, A; Pluim, D; Scheffer, GL; Schellens, JH; van Eijndhoven, MA | 1 |
| AFlint, JA; Ardelt, B; Coradetti, T; Darzynkiewicz, Z; Davidowitz, H; Huang, Z; Lin, X; Mandecki, W; MKopacka, WM; Wang, Z | 1 |
| Allen, JD; Arnold, JC; Holland, ML; Lau, DT | 1 |
| Darzynkiewicz, Z; Traganos, F; Zhao, H | 2 |
| Enomoto, T; Hayashi, K; Iizuka, M; Kuranami, M; Nakakuma, T; Sengoku, N; Watanabe, M; Yoshimura, N | 1 |
| Karp, J | 1 |
| Dudgeon, DD; Giuliano, KA; Johnston, PA; Lazo, JS; Shinde, SN; Shun, TY; Strock, CJ; Taylor, DL | 1 |
| Darzynkiewicz, Z; Dobrucki, J; Rybak, P; Traganos, F; Zhao, H | 1 |
| Deng, Y; Ma, Y; Wang, L; Yang, Q; Zhao, Y; Zhou, X | 1 |
| Fu, LW; Liang, YJ; Su, XD; Wang, F; Wu, XP | 1 |
| Ambudkar, SV; Baer, MR; Bhullar, J; Cai, L; Chen, ZS; Fang, HB; Natarajan, K; Sen, R; Shukla, S | 1 |
| Patel, KJ; Tannock, IF; Trédan, O | 1 |
| Audisio, E; Boccadoro, M; Bruno, B; Crisà, E; Ferrero, D; Festuccia, M; Frairia, C; Gatti, T; Giai, V; Marmont, F; Passera, R; Riera, L | 1 |
| Chen, L; Chen, Z; Fu, L; Li, F; Wang, F; Wang, X; Zhang, W | 1 |
| Barbuti, AM; Chen, ZS; Wang, YJ; Wen, AW; Wurpel, JND; Yu, XY; Zhang, GN; Zhang, YK; Zhu, XJ | 1 |
| Jiang, S; Lan, S; Ma, D; Mao, D; Shi, K; Yang, X | 1 |
| Altman, JK; Broun, ER; Carroll, MP; Karp, JE; Kaufmann, SH; Ketterling, RP; Lazarus, HM; Litzow, MR; Luger, SM; Paietta, EM; Pratz, KW; Rowe, JM; Rybka, WB; Tallman, MS; Tun, HW; Wang, XV; Zhang, Y | 1 |
| Al-Rihani, SB; Ambudkar, SV; Chen, ZS; Kaddoumi, A; Lei, ZN; Shi, Z; Shukla, S; Wang, DS; Wang, YJ; Zhang, GN; Zhang, XY; Zhang, YK | 1 |
| Cannon, RE; Perera, L; Sinha, BK | 1 |
4 review(s) available for topotecan and mitoxantrone
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bone Marrow Transplantation; Combined Modality Therapy; Cyclosporine; Cystitis; Cytarabine; Cytomegalovirus Infections; DNA, Neoplasm; Female; Foscarnet; Ganciclovir; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Histocompatibility; Humans; Hydroxyurea; Immunosuppressive Agents; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Methotrexate; Mitoxantrone; Neoplasms, Second Primary; Prednisolone; Prostaglandins; Remission Induction; Topotecan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2001 |
[Drug-resistant proteins in breast cancer: recent progress in multidrug resistance].
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Mitoxantrone; Neoplasm Proteins; Topotecan; Tumor Cells, Cultured | 2003 |
4 trial(s) available for topotecan and mitoxantrone
| Article | Year |
|---|---|
Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; DNA Fragmentation; DNA Topoisomerases, Type II; Enzyme Induction; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Topotecan | 2002 |
A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Demography; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Survival Rate; Topotecan; Treatment Outcome | 2004 |
Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Proportional Hazards Models; Remission Induction; Risk; Survival Analysis; Topotecan; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2014 |
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Flavonoids; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Recurrence; Remission Induction; Salvage Therapy; Sirolimus; Topotecan; Tumor Lysis Syndrome | 2019 |
60 other study(ies) available for topotecan and mitoxantrone
| Article | Year |
|---|---|
Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Breast Neoplasms; Cell Survival; Diethylstilbestrol; Drug Resistance, Neoplasm; Estrogen Antagonists; Estrogens; Estrone; Female; Humans; K562 Cells; Kinetics; Mitoxantrone; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Tamoxifen; Topotecan; Tumor Cells, Cultured | 2003 |
Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Availability; Biological Transport; Cell Line; Dogs; Drug Resistance, Neoplasm; Etoposide; Male; Mice; Mice, Knockout; Neoplasm Proteins | 2003 |
Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Biological Transport; Cell Membrane; Drug Resistance, Microbial; Drug Resistance, Multiple; Ligands; Models, Molecular | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Synthesis and topoisomerase poisoning activity of A-ring and E-ring substituted luotonin A derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Humans; Magnetic Resonance Spectroscopy; Pyrroles; Quinones; Spectrometry, Mass, Electrospray Ionization; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
Topics: Candida albicans; Membrane Transport Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Substrate Specificity | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs | 2013 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations.
Topics: Antineoplastic Agents; Breast Neoplasms; Camptothecin; Cell Survival; DNA Topoisomerases, Type I; Drug Resistance; Female; Humans; Mitoxantrone; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1995 |
Cytotoxic efficacy with combinations of topoisomerase I and topoisomerase II inhibitors in sensitive and multidrug-resistant L1210 mouse leukemia cells.
Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Multiple; Drug Synergism; Enzyme Inhibitors; Etoposide; Leukemia L1210; Mice; Mitoxantrone; Topoisomerase I Inhibitors; Topotecan | 1996 |
Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Survival; DNA, Neoplasm; Female; Humans; Hydrogen-Ion Concentration; Mammary Neoplasms, Experimental; Mice; Mitoxantrone; Paclitaxel; Topotecan; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1997 |
The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin.
Topics: 3T3 Cells; Amino Acid Sequence; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; DNA, Complementary; Doxorubicin; Drug Resistance, Neoplasm; Gene Amplification; Mice; Mitoxantrone; Molecular Sequence Data; RNA, Messenger; Topotecan | 1999 |
Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Drug Resistance, Multiple; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Kinetics; Mitoxantrone; Neoplasm Proteins; Ovarian Neoplasms; Topotecan; Tumor Cells, Cultured | 1999 |
Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Cell Survival; DNA Damage; Drug Resistance, Multiple; Epirubicin; Female; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Microscopy, Confocal; Mitoxantrone; Polymerase Chain Reaction; Topotecan; Tumor Cells, Cultured | 1999 |
Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Membrane; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Inbred BALB C; Mitoxantrone; Neoplasm Proteins; Topotecan; Tumor Cells, Cultured | 2000 |
Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
Topics: Acridines; Administration, Oral; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Availability; DNA, Complementary; Enzyme Inhibitors; Female; Fetus; Humans; Intestinal Absorption; Isoquinolines; Male; Mice; Mitoxantrone; Neoplasm Proteins; Placenta; Pregnancy; RNA, Messenger; Tetrahydroisoquinolines; Topotecan | 2000 |
Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mitoxantrone; Neoplasm Proteins; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 2000 |
Action of topoisomerase targeting drugs on non-Hodgkin's lymphoma and leukemia. Correlation of clinical and cell culture studies.
Topics: Acute Disease; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Cytarabine; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Isoenzymes; Leukemia; Leukocytes; Lymphoma, Non-Hodgkin; Mitoxantrone; Polymerase Chain Reaction; RNA, Messenger; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 2000 |
A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; DNA Damage; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression; HT29 Cells; Humans; Mice; Mice, Nude; Mitoxantrone; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Topotecan; Xenograft Model Antitumor Assays | 2001 |
Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Genes, MDR; Genetic Vectors; HeLa Cells; Humans; Irinotecan; Mitoxantrone; Mutation; Neoplasm Proteins; Rhodamine 123; RNA, Messenger; Substrate Specificity; Topotecan; Transfection; Tumor Cells, Cultured; Vaccinia virus | 2001 |
Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrone; Female; Flow Cytometry; Humans; Irinotecan; K562 Cells; Mitoxantrone; Neoplasm Proteins; Topoisomerase I Inhibitors; Topotecan; Transfection | 2002 |
Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Topics: Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Nucleus; Cell Survival; Comet Assay; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Etoposide; Fluorescent Antibody Technique; Humans; K562 Cells; Microscopy, Confocal; Mitoxantrone; Topotecan | 2002 |
Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Northern; Blotting, Western; Caspase 3; Caspases; Cell Division; DNA, Complementary; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme-Linked Immunosorbent Assay; Genetic Vectors; Humans; Interleukin-6; Interleukin-8; Mitoxantrone; Osteosarcoma; Paclitaxel; Phenotype; RNA; Tetrazolium Salts; Thiazoles; Time Factors; Topotecan; Transfection; Tumor Cells, Cultured | 2002 |
Low levels of ABCG2 expression in adult AML blast samples.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood Cells; Bone Marrow Cells; Drug Resistance, Neoplasm; Female; Fetal Blood; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Humans; Idarubicin; Infant, Newborn; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Neoplastic Stem Cells; RNA, Messenger; RNA, Neoplasm; Topotecan | 2002 |
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; In Vitro Techniques; Indoles; Intestines; Mice; Mitoxantrone; Mycotoxins; Neoplasm Proteins; Topotecan; Transfection; Tumor Cells, Cultured; Vincristine | 2002 |
C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.
Topics: Alternative Splicing; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Base Sequence; Blotting, Northern; Blotting, Western; Camptothecin; DNA, Complementary; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fibroblasts; Heterozygote; Homozygote; Irinotecan; Mice; Mitoxantrone; Molecular Sequence Data; Mutation; Neoplasm Proteins; Polymorphism, Genetic; RNA, Messenger; Sequence Analysis, DNA; Topotecan; Transfection; Tumor Cells, Cultured | 2002 |
The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells.
Topics: Animals; Antineoplastic Agents; BRCA1 Protein; Busulfan; Camptothecin; Cell Division; Cell Line; Doxorubicin; Etoposide; Fibroblasts; Gene Deletion; Genes, BRCA1; Mice; Mitoxantrone; Topotecan; Tumor Suppressor Protein p53 | 2003 |
Expression and functional analyses of breast cancer resistance protein in lung cancer.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Protein Transport; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topotecan | 2003 |
Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Topics: Aminocoumarins; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Coumarins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Novobiocin; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 2004 |
Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-linking agent cisplatin.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Caspase Inhibitors; Caspases; Cell Cycle; Chromatin Assembly and Disassembly; Cisplatin; Cross-Linking Reagents; DNA; Enzyme Activation; Histones; HL-60 Cells; Humans; Mitoxantrone; Phosphorylation; Protein Binding; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 2004 |
Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cells; Choriocarcinoma; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Estradiol; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Mitoxantrone; Neoplasm Proteins; Pregnancy; RNA Interference; RNA, Messenger; Topotecan; Tumor Cells, Cultured; Uterine Neoplasms | 2004 |
Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Topics: Adenosine Triphosphate; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Breast Neoplasms; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Cell Membrane; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Topotecan | 2005 |
Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cell Survival; Dihydropyridines; Drug Interactions; Drug Resistance, Multiple; Female; Humans; Inhibitory Concentration 50; Mitoxantrone; Neoplasm Proteins; Pyridines; Rats; Rats, Sprague-Dawley; Topotecan | 2005 |
Assessment of ATM phosphorylation on Ser-1981 induced by DNA topoisomerase I and II inhibitors in relation to Ser-139-histone H2AX phosphorylation, cell cycle phase, and apoptosis.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Caffeine; Cell Cycle; Cell Cycle Proteins; Cell Nucleus; Cytoplasm; DNA-Binding Proteins; Flow Cytometry; Histones; HL-60 Cells; Humans; Immunohistochemistry; Interphase; Kinetics; Mitoxantrone; Phosphorylation; Protein Serine-Threonine Kinases; Serine; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Topotecan; Tumor Suppressor Proteins | 2005 |
Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cyclosporine; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Immunosuppressive Agents; Mitoxantrone; Neoplasm Proteins; Sirolimus; Substrate Specificity; Tacrolimus; Topotecan | 2006 |
Activation of ATM and histone H2AX phosphorylation induced by mitoxantrone but not by topotecan is prevented by the antioxidant N-acetyl-L-cysteine.
Topics: Acetylcysteine; Antineoplastic Agents; Antioxidants; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle; Cell Cycle Proteins; DNA Damage; DNA-Binding Proteins; Flow Cytometry; Fluorescent Antibody Technique; Histones; HL-60 Cells; Humans; Lung Neoplasms; Mitoxantrone; Phosphorylation; Protein Serine-Threonine Kinases; Topotecan; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2006 |
Important differences between topoisomerase-I and -II targeting agents.
Topics: Acetylcysteine; Antineoplastic Agents; Antioxidants; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; DNA Damage; DNA-Binding Proteins; Histones; Humans; Mitoxantrone; Phosphorylation; Protein Serine-Threonine Kinases; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2006 |
The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Breast Neoplasms; Cell Line; Cell Line, Tumor; Dogs; Female; Folic Acid; Humans; Hydrogen-Ion Concentration; Kinetics; Liver; Methotrexate; Mitoxantrone; Neoplasm Proteins; Rabbits; Resveratrol; Stilbenes; Topotecan | 2007 |
Microtransponders, the miniature RFID electronic chips, as platforms for cell growth in cytotoxicity assays.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Transitional Cell; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cost Control; Drug Screening Assays, Antitumor; Electronics; Humans; Lab-On-A-Chip Devices; Laser Scanning Cytometry; Lung Neoplasms; Microchip Analytical Procedures; Microscopy, Fluorescence; Mitoxantrone; Radio Waves; Ribonucleases; Topotecan | 2006 |
The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cannabinoids; Cell Line; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Dronabinol; Flow Cytometry; Humans; Immunoblotting; Inhibitory Concentration 50; Mice; Mitoxantrone; Neoplasm Proteins; Plant Extracts; Receptor, Cannabinoid, CB1; Reverse Transcriptase Polymerase Chain Reaction; Sulfasalazine; Topotecan; TRPV Cation Channels | 2007 |
Kinetics of histone H2AX phosphorylation and Chk2 activation in A549 cells treated with topotecan and mitoxantrone in relation to the cell cycle phase.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 2; DNA Damage; Enzyme Activation; Histones; Humans; Immunohistochemistry; Kinetics; Microscopy, Confocal; Mitoxantrone; Phosphorylation; Protein Serine-Threonine Kinases; Topotecan | 2008 |
Phosphorylation of p53 on Ser15 during cell cycle caused by Topo I and Topo II inhibitors in relation to ATM and Chk2 activation.
Topics: Ataxia Telangiectasia Mutated Proteins; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Checkpoint Kinase 2; DNA Damage; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Enzyme Inhibitors; Fluorescent Antibody Technique; Humans; Mitoxantrone; Phosphorylation; Protein Serine-Threonine Kinases; Serine; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2008 |
[A case of stage IV breast cancer in which a long-term no change state (NC) was attained by a combination of S-1 and TAM following AC-T as a primary systemic therapy (PST)].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Combinations; Female; Humans; Mitoxantrone; Neoplasm Staging; Oxonic Acid; Paclitaxel; Tegafur; Time Factors; Tomography, X-Ray Computed; Topotecan | 2008 |
Future research directions for the treatment of AML.
Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin | 2008 |
Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2.
Topics: Antineoplastic Agents; Biosensing Techniques; Camptothecin; Cell Line, Tumor; Checkpoint Kinase 2; Ellipticines; Genes, p53; High-Throughput Screening Assays; Humans; Imidazoles; Mitoxantrone; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-mdm2; Recombinant Fusion Proteins; Small Molecule Libraries; Spectrometry, Fluorescence; Topotecan; Tumor Suppressor Protein p53 | 2010 |
Relationship of DNA damage signaling to DNA replication following treatment with DNA topoisomerase inhibitors camptothecin/topotecan, mitoxantrone, or etoposide.
Topics: Camptothecin; Cell Line, Tumor; DNA Damage; DNA Replication; Etoposide; Histones; Humans; Mitoxantrone; Phosphorylation; Signal Transduction; Topoisomerase Inhibitors; Topotecan | 2012 |
Repeated injections of PEGylated liposomal topotecan induces accelerated blood clearance phenomenon in rats.
Topics: Animals; Doxorubicin; Immunoglobulin M; Liposomes; Male; Metabolic Clearance Rate; Mitoxantrone; Phospholipids; Polyethylene Glycols; Rats; Rats, Wistar; Topotecan | 2012 |
ABCG2-overexpressing S1-M1-80 cell xenografts in nude mice keep original biochemistry and cell biological properties.
Topics: Adenosine; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Colonic Neoplasms; Diketopiperazines; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Inhibitory Concentration 50; KB Cells; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitoxantrone; Neoplasm Proteins; Neoplasm Transplantation; Rhodamine 123; Topotecan | 2012 |
The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carbocyanines; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Chlorophyll; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; fms-Like Tyrosine Kinase 3; Fusion Proteins, bcr-abl; Humans; Imidazoles; Inhibitory Concentration 50; Mitoxantrone; Neoplasm Proteins; Protein Binding; Pyridazines; Rhodamine 123; Topotecan | 2012 |
Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Line, Tumor; Coronary Vessels; Doxorubicin; Female; Humans; Kidney; Liver; Mice; Mice, Nude; Mitoxantrone; Myocardium; Neoplasms; Neovascularization, Pathologic; Tissue Distribution; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays | 2013 |
ABCG2-overexpressing H460/MX20 cell xenografts in athymic nude mice maintained original biochemical and cytological characteristics.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Disease Models, Animal; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Heterografts; Lapatinib; Mice, Nude; Mitoxantrone; Neoplasm Proteins; Neoplasm Transplantation; Quinazolines; Topotecan | 2017 |
Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib.
Topics: Anilides; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line, Tumor; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Mitoxantrone; Molecular Docking Simulation; Neoplasms; Pyridines; Topoisomerase I Inhibitors; Topotecan | 2017 |
Pro-guest and acyclic cucurbit[n]uril conjugated polymers for the controlled release of anti-tumor drugs.
Topics: Antineoplastic Agents; Berberine; Bridged-Ring Compounds; Camptothecin; Doxorubicin; Drug Carriers; Drug Liberation; Fluorescent Dyes; HeLa Cells; Humans; Hydrogen-Ion Concentration; Imidazoles; Irinotecan; Mitoxantrone; Polymers; Topotecan | 2018 |
Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; Binding Sites; Cell Line, Tumor; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Humans; Male; Mice, Nude; Mitoxantrone; Molecular Docking Simulation; Molecular Dynamics Simulation; Neoplasm Proteins; Phenylurea Compounds; Protein Binding; Protein Conformation; Pyridines; Topotecan; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Reversal of drug resistance by JS-K and nitric oxide in ABCB1- and ABCG2-expressing multi-drug resistant human tumor cells.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Azo Compounds; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Mitoxantrone; Molecular Docking Simulation; Molecular Structure; Nitric Oxide; Nitroso Compounds; Piperazines; Topotecan | 2019 |